FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Sun Pharmaceutical Industries Decitabine for Injection 50mg per vial Recall

Decitabine for Injection 50mg per vial, For intravenous infusion only Cytotoxic Agent,…

SUN PHARMACEUTICAL INDUSTRIES INC · Princeton, NJ

Risk level
Class II
Reported by FDA
Jul 10, 2024
Recall ID
D-0582-2024
Check your lot numberHow we source this data

Summary

Sun Pharmaceutical Industries recalled Decitabine for Injection 50mg per vial starting Jul 2, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0582-2024 on Jul 10, 2024. Reason: CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection. Status: Ongoing.

Why it was recalled

CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.

Product description

Decitabine for Injection 50mg per vial, For intravenous infusion only Cytotoxic Agent, Sterile, Rx Only, Single-Dose Vial, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 47335-361-40.

Lot numbers, UPCs & expiration codes

HAD2964A, Exp 7/31/2024

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0582-2024
Classification
Class II
Status
Ongoing
Recall initiated
Jul 2, 2024
FDA report date
Jul 10, 2024
Quantity
2088 vials
Recall type
Voluntary: Firm initiated
Recalling firm
SUN PHARMACEUTICAL INDUSTRIES INC

Original FDA data

Every field from FDA enforcement report D-0582-2024, exactly as published.

Show all FDA fields
City
Princeton
State
NJ
Status
Ongoing
Country
United States
Event ID
94913
Address
2 Independence Way
Code information
HAD2964A, Exp 7/31/2024
Postal code
08540-6620
Report date
Jul 10, 2024
Product type
Drugs
Recall number
D-0582-2024
Classification
Class II
Recalling firm
SUN PHARMACEUTICAL INDUSTRIES INC
Product quantity
2088 vials
Reason for recall
CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Decitabine for Injection 50mg per vial, For intravenous infusion only Cytotoxic Agent, Sterile, Rx Only, Single-Dose Vial, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 47335-361-40.
Distribution pattern
Nationwide in the USA
Recall initiation date
Jul 2, 2024
Initial firm notification
Letter
Center classification date
Jul 3, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0582-2024, published Jul 10, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls